| 楼晓清,应茵.吉非替尼与多西他赛两种药物治疗非小细胞肺癌相比较的Meta分析[J].浙江中西医结合杂志,2015,25(6): |
| 吉非替尼与多西他赛两种药物治疗非小细胞肺癌相比较的Meta分析 |
| Meta-analysis of gefitinib and docetaxel for non-small cell lung cancer (NSCLC) |
| 投稿时间：2014-09-25 修订日期：2014-12-24 |
| DOI： |
| 中文关键词: 非小细胞肺癌 吉非替尼 多西他赛 Meta 分析 |
| 英文关键词:gefitinib docetaxel non- small cell lung cancer Meta analysis |
| 基金项目:浙江省中西医结合学会科研项目2013LYZD009 |
|
| 摘要点击次数: 758 |
| 全文下载次数: 0 |
| 中文摘要: |
| 目的：利用meta分析的方法评价吉非替尼与多西他赛两种药物治疗晚期非小细胞肺癌的临床疗效和安全性。方法：计算机检Cochrane Library、PubMed、中国知网数据库、中国生物医学文献数据库、中文科技期刊全文数据库,检索时间从数据库建库至2014 年9月,同时辅助其它检索,纳入吉非替尼与多西他赛两种药物治疗非小细胞肺癌(NSCLC)的随机对照试验(randomized controlled trials,RCTs)。并用Stata 9.0软件进行统计分析。结果：共纳入13篇文献,包括3307例非小细胞肺癌患者。分析结果显示：吉非替尼治疗非小细胞肺癌与多西他赛相比,吉非替尼可以提高非小细胞肺癌患者的总有效率(OR = 1.69,95% CI = 1.34-2.12)、TOI改善率(OR = 2.43,95% CI = 1.95-3.03)、及降低中性粒细胞减少发生率(OR = 0.03,95% CI = 0.02-0.06)。结论：与多西他赛相比,吉非替尼显示提高了患者的总有效率,TOL改善得到了提高,降低了中性粒细胞减少的发生率；但仍需高质量的研究证明其有效性和安全性。 |
| 英文摘要: |
| 【】 Objective: To explore the clinical efficacy and safety of gefitinib and docetaxel for NSCLC by a meta-analysis method．Methods: PubMed,Medline,ISI, CNKI,VIP,and Wanfang database were searched (up to Sep.2014). RCTs of gefitinib and docetaxel for NSCLC were included. Meta-analyses were performed by Stata 9.0 software. Results: 13 randomized controlled trials(ＲCTs) involving 3307 NSCLC patients were included in this meta-analysis. The results of meta-analyses showed that: compared to docetaxel,gefitinib could improve over response rate (OR = 1.69,95% CI = 1.34-2.12) and TOI (OR = 2.43,95% CI = 1.95-3.03) with lower hematology toxicity rate (OR = 0.03,95% CI = 0.02-0.06). Conclusion:Gefitinib shows more superiority for NSCLC compared to docetaxel． High qualityＲCTs and economic evaluation are needed． |
| 查看全文 查看/发表评论 下载PDF阅读器 |
| 关闭 |
|
|
|
